The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

The Big Three PBMs have largely criticized the FTC report. A spokesperson for CVS Health argued that the FTC has drawn broad conclusions from “cherry-picked” specialty generic outliers in both ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their ...

CVS Health, UnitedHealth Group and Cigna share prices dipped midday after the FTC released its report, but each company rebounded and was up slightly when the New York Stock Exchange closed Tuesday.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.